Maria Brown Email

Validation Manager . WuXi Advanced Therapies

Current Roles

Employees:
520
Revenue:
$80.6M
About
Accelerating the Progress and Time to Market of Bio-Based Drugs through Integrated Manufacturing and Laboratory Testing Services Our Story By leveraging platforms and integrated testing, the Advanced Therapies business unit of WuXi AppTec is a streamlined Contract Development and Manufacturing Organization (CDMO), pioneering the expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. Well positioned for growth, our investments in personnel and manufacturing continue to expand clinical and commercial capacities. Since 2004, WuXi AppTec has supported Advanced Therapy programs with an extensive infrastructure of state-of-the-art, GMP-compliant facilities, providing centers of excellence for manufacturing and testing. Our Vision To significantly contribute to the growth of Advanced Therapies by accelerating and transforming development and manufacturing through our enabling platforms and technologies to the benefit of patients worldwide.
WuXi Advanced Therapies Address
4751 League Island Blvd
Philadelphia, PA
United States
WuXi Advanced Therapies Email
WuXi Advanced Therapies Phone Numbers
212-185-500

Past Companies

WuXi Advanced TherapiesValidation Manager
WuXi Advanced TherapiesTechnical Transfer Manager
WuXi Advanced TherapiesSenior Scientist

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.